Amneal Pharmaceuticals (AMRX) Retained Earnings (2017 - 2026)
Amneal Pharmaceuticals has reported Retained Earnings over the past 9 years, most recently at -$535.0 million for Q4 2025.
- For Q4 2025, Retained Earnings fell 716.68% year-over-year to -$535.0 million; the TTM value through Dec 2025 reached -$535.0 million, down 716.68%, while the annual FY2025 figure was -$535.0 million, 716.68% down from the prior year.
- Retained Earnings for Q4 2025 was -$535.0 million at Amneal Pharmaceuticals, down from -$105.9 million in the prior quarter.
- Over five years, Retained Earnings peaked at $9.9 million in Q4 2022 and troughed at -$581.8 million in Q1 2024.
- A 5-year average of -$292.8 million and a median of -$277.3 million in 2021 define the central range for Retained Earnings.
- Biggest five-year swings in Retained Earnings: surged 103.6% in 2022 and later tumbled 14971.7% in 2024.
- Year by year, Retained Earnings stood at -$276.2 million in 2021, then surged by 103.6% to $9.9 million in 2022, then crashed by 425.48% to -$32.3 million in 2023, then crashed by 102.51% to -$65.5 million in 2024, then tumbled by 716.68% to -$535.0 million in 2025.
- Business Quant data shows Retained Earnings for AMRX at -$535.0 million in Q4 2025, -$105.9 million in Q3 2025, and -$572.4 million in Q2 2025.